rare-diseases-2016_scientifictracks-workshop

24 / 30

Page 55
Notes:
conferenceseries.com
October 26-27, 2016 Chicago, USA
Annual Congress on
Rare Diseases & Orphan Drugs
Volume 7, Issue 5 (Suppl) J Genet Syndr Gene Ther
ISSN: 2157-7412 JGSGT, an open access journal Rare Diseases 2016
October 26-27, 2016
Rare disease studies facilitated by taking study visits to the patients
Gail Adinamis
GlobalCare Clinical Trials LLC, USA
Patient recruitment and retention are key factors in establishing the objectives and ultimate success of clinical trials. These can be
particularly challenging in rare disease studies where patients reside distant to investigator sites and may suffer from debilitating
diseases making travel difficult. Patient advocacy groups have been playing a more influential role in drug development and
commercialization especially in rare diseases. Advocacy groups represent the voice of the patient contributing to better clinical trial
design by helping to remove barriers that made participation difficult or impossible. But many challenges remain. A patient-centric
service model has evolved over the past years allowing study visits to be conducted at the patient's home where it is more convenient
and comfortable than at the investigator site. By conducting selected protocol visits at home, workplace or other alternate location,
ambulant healthcare providers offer a way for patients to participate in trials regardless of study duration, frequency of visits, disease
state, distance to site and family, school, work or community obligations. By making trials more convenience and comfortable for
patients, more patients are willing and able to participate and remain in the study. This innovative service model is available on a
global basis and has been shown to triple enrollment rates and reduce patient dropout rates to 3 percent. Services include study drug
administration, blood draws, clinical assessments, patient training and education and study compliance checks in all age groups, a
variety of therapeutic areas and in all phases of development. This ambulant care service model provides a win-win benefit for all
stake holders by providing patient's a convenient and comfortable way to participate in studies, offering investigators the ability to
recruit patients from broader geographic areas, reducing development times for sponsors developing new therapeutics and ultimately
getting life enhancing products to consumers sooner.
Biography
Gail Adinamis is the Founder and CEO of GlobalCare Clinical Trials LLC, USA and has over 35 years of comprehensive global clinical trials experience including
over 12 years of global trials management at Abbott Laboratories and Astellas. She has founded the in-home business model for study visits in 1992 and established
and headed clinical trials divisions for three national home infusion companies and was the Founder, President and CEO of the first independent ambulant care
service company for clinical trials. She is a Member of the Women Presidents’ Organization, National Association of Professional Women and DIA and has been
an invited speaker at several industry conferences and recipient of numerous awards/recognitions including twice being among INC 5000’s fastest growing private
companies and Game Changer and CEO of the Year.
Gail Adinamis, J Genet Syndr Gene Ther 2016, 7:5 (Suppl)